Drug
SYN-004
SYN-004 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
completed375%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
unknownphase_1
A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions
NCT04363242
completedphase_1
A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy
NCT02473640
completedphase_2
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
NCT02563106
completedphase_1
Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors
NCT02391727
Clinical Trials (4)
Showing 4 of 4 trials
NCT04363242Phase 1
A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions
NCT02473640Phase 1
A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy
NCT02563106Phase 2
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
NCT02391727Phase 1
Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4